Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies (NASDAQ: AKTS) will webcast its Q1 FY23 financial results on November 14, 2022, at 8:00 AM ET. A question-and-answer session will follow. To listen, call 877-407-3982 (domestic) or 201-493-6780 (international). The company is ramping up production capacity to about 0.5 billion filters annually at its New York facility. Akoustis is actively shipping its Wi-Fi 6 tandem filters and has secured over 20 customer design wins for its patented XBAW® filters.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced three new Wi-Fi 6E design wins for carrier-class applications, including two wins from a leading European Wi-Fi OEM and one from a global network provider. The design wins utilize 4x4 MU-MIMO architectures, with production expected to ramp for the first router by the end of 2022 and additional routers in 2023. Akoustis anticipates further growth in its customer base, driven by increasing interest in its advanced Wi-Fi solutions. The company is investing in its production capacity, targeting approximately 500 million units annually.
Akoustis Technologies (NASDAQ: AKTS) has joined the Semiconductor Industry Association (SIA) as a Charter Member, aligning with major industry leaders like Intel and Qualcomm. This membership aims to enhance U.S. semiconductor innovation and competitiveness, particularly following the CHIPS and Science Act of 2022. The company is currently ramping up production capacity to approximately 500 million units annually and has secured over 20 customer design wins for its proprietary XBAW filter solutions, including Wi-Fi 6 and 5G products.
Charlotte, N.C., Oct. 04, 2022 – Akoustis Technologies (NASDAQ: AKTS) has introduced two new Wi-Fi 6E and Wi-Fi 7 RF filter solutions, A10655 and A10665, now in sampling phase. These filters target U-NII 1-3 and U-NII 5-8 frequency bands, boasting a 4X smaller form factor and superior out-of-band rejection. Production is anticipated to commence in H1 2023, with plans to reach an annual capacity of approximately 500 million units. Over 20 design wins for XBAW filters have already been secured, underlining Akoustis's growth in the multi-billion-dollar RF filter market.
Akoustis Technologies has secured a design win for its 3.5 GHz XBAW filter from a new 5G mobile network infrastructure customer, marking its fourth such win. The filters will be integrated into small cell and MIMO applications targeted for Europe and Asia, with production set to begin by the end of 2022. This initiative highlights Akoustis' growth in the 5G market and builds on its 500 million unit production capacity goal. The company has over 20 design wins for its XBAW filters.
Akoustis Technologies (NASDAQ: AKTS) announced the development of a new 5G mobile XBAW filter for a tier-1 RF module maker, following a purchase order received in December 2021. The filter aims to address difficult coexistence frequency band requirements in 5G mobile technology. Production is planned for 2024, with initial sample deliveries expected in late 2022. Akoustis is ramping up its commercial production, targeting annual capacity of approximately 500 million units and has achieved over 20 design wins for its XBAW filter solutions.
Akoustis Technologies (AKTS) reported a record revenue of $5.2 million for Q4 FY22, reflecting a 140% year-over-year increase. The company anticipates a greater than 200% rise in revenue for the current quarter, supported by strong demand across multiple sectors, including 5G and Wi-Fi. Despite supply chain challenges, Akoustis is expanding its chip manufacturing in New York, potentially benefiting from the CHIPS Act. The company has achieved 12 production customers and increased its annual production capacity to 0.5 billion filters.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced two significant design wins in the gaming market for their Wi-Fi 6E XBAW® filter products. The first design win is for a gaming router utilizing MU-MIMO architecture, while the second is for a leading end-user gaming device. Both products are set to ramp production by mid-calendar 2023. Akoustis aims to enhance data throughput and reduce latency, as these innovations signal growing interest beyond their core router market. The company is ramping its commercial production capacity to approximately 500 million units annually.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced the successful tour of its semiconductor fab by Senate Majority Leader Charles Schumer, highlighting the impact of the CHIPS and Science Act of 2022. This bipartisan legislation allocates over $52 billion to boost U.S. semiconductor manufacturing and science innovation. Akoustis anticipates significant opportunities for growth, particularly in the Rochester area, where the company aims to produce billions of RF filter chips annually for 5G networks and other wireless applications. Akoustis has invested over $65 million in its NY facility, aiming for a production capacity of approximately 500 million units.
Akoustis Technologies (NASDAQ: AKTS) is set to enter production of its new filters by late 2023. The company has developed and shipped a second iteration of a 5G XBAW® filter to a customer, aiming for volume production in mid-2023. Additionally, Akoustis received a development order for two new XBAW® filters targeting the Wi-Fi 6E access point market. The company is ramping up commercial production with a goal of 500 million units annually and has secured over 20 design wins for its patented filter solutions.